CDKN2A and astrocytoma (excluding glioblastoma): To our knowledge, this is the first study to assess prognostic factors in the clinically relevant entities of IDH-mutated astrocytoma and oligodendroglioma, respectively, without known CDKN2A/B homozygous deletions.